title: Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.
abstract: Imidazo[4,5-c]quinoline derivatives have been discovered and developed as potent and effective modulators of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway to lead to clinical development candidates. The SAR data of representative examples of this compound class and their biological profiling in cellular and in vivo settings are presented and discussed.
authors.affiliation: Novartis Institute for BioMedical Research, Oncology Drug Discovery, Klybeckstrasse 141, Postfach, CH-4002 Basel, Switzerland. frederic.stauffer@novartis.com
authors.forename: Frédéric
authors.initials: F
authors.lastname: Stauffer
authors.forename: Sauveur-Michel
authors.initials: SM
authors.lastname: Maira
authors.forename: Pascal
authors.initials: P
authors.lastname: Furet
authors.forename: Carlos
authors.initials: C
authors.lastname: García-Echeverría
mesh_terms: D000818:Animals; D007093:Imidazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D008819:Mice, Nude; D015394:Molecular Structure; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D011804:Quinolines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D007093:Imidazoles; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011804:Quinolines; D051057:Proto-Oncogene Proteins c-akt